New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Scribe Therapeutics Inc.

SCTX

Healthcare Biotechnology

Scribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.

12.07 1.15 −8.70%

After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.

Market cap
$250.4M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
n/a
ROIC
—
Net debt / EBITDA
—
Payout ratio
—

Scribe Therapeutics Inc. 8-K filed Nov 12, 2026

Period ended Nov 12, 2026 · Filed · accepted 4:20 PM ET · Document on sec.gov · Filing index

Read the filing on sec.gov

2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above, and the document itself is on sec.gov.

The press release